两种旧的免疫抑制剂甲氨蝶呤和硫唑嘌呤治疗扁平苔藓的临床疗效:随机临床试验

IF 3.7 4区 医学 Q1 DERMATOLOGY Dermatologic Therapy Pub Date : 2024-06-19 DOI:10.1155/2024/5556945
Mina Saber, Parisa Hajheidari, Farahnaz Fatemi Naeini, Fatemeh Mohaghegh
{"title":"两种旧的免疫抑制剂甲氨蝶呤和硫唑嘌呤治疗扁平苔藓的临床疗效:随机临床试验","authors":"Mina Saber,&nbsp;Parisa Hajheidari,&nbsp;Farahnaz Fatemi Naeini,&nbsp;Fatemeh Mohaghegh","doi":"10.1155/2024/5556945","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Background</i>. Lichen planopilaris is the leading cause of cicatricial alopecia, and its management is challenging for dermatologists. It is a cell-mediated autoimmune disorder in which activated T-lymphocytes attack hair follicles. <i>Aim</i>. To compare the efficacy and safety of methotrexate versus azathioprine, two medications that affect lymphocyte function, in treating LPP. <i>Methods</i>. 32 LPP patients were randomly assigned to receive either 15 mg/week methotrexate or 2 mg/kg azathioprine for six months. Treatment efficacy was evaluated using the Lichen Planopilaris Activity Index (LPPAI), trichoscopy, and photography after 2, 4, and 6 months of treatment. <i>Results</i>. Both methotrexate and azathioprine groups showed significant improvements in LPPAI (<i>P</i> &lt; 0.001) and perifollicular scaling on trichoscopy (<i>P</i> &lt; 0.01). However, the two groups had no significant difference during the study. The azathioprine group significantly improved perifollicular erythema on trichoscopy (<i>P</i> = 0.002), but this was not significantly different from the methotrexate group (<i>P</i> = 0.69). Photographic assessment showed that more than 75% of patients in both groups improved without significant differences between the two groups. <i>Conclusion</i>. Methotrexate and azathioprine are two antilymphocyte medications which are both equally effective and well-tolerated for managing LPP. This trial is registered with IRCT20191006045005N2.</p>\n </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2024 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5556945","citationCount":"0","resultStr":"{\"title\":\"Clinical Effectiveness of Two Old Immunosuppressant Drugs, Methotrexate and Azathioprine, in the Treatment of Lichen Planopilaris: A Randomized Clinical Trial\",\"authors\":\"Mina Saber,&nbsp;Parisa Hajheidari,&nbsp;Farahnaz Fatemi Naeini,&nbsp;Fatemeh Mohaghegh\",\"doi\":\"10.1155/2024/5556945\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n <p><i>Background</i>. Lichen planopilaris is the leading cause of cicatricial alopecia, and its management is challenging for dermatologists. It is a cell-mediated autoimmune disorder in which activated T-lymphocytes attack hair follicles. <i>Aim</i>. To compare the efficacy and safety of methotrexate versus azathioprine, two medications that affect lymphocyte function, in treating LPP. <i>Methods</i>. 32 LPP patients were randomly assigned to receive either 15 mg/week methotrexate or 2 mg/kg azathioprine for six months. Treatment efficacy was evaluated using the Lichen Planopilaris Activity Index (LPPAI), trichoscopy, and photography after 2, 4, and 6 months of treatment. <i>Results</i>. Both methotrexate and azathioprine groups showed significant improvements in LPPAI (<i>P</i> &lt; 0.001) and perifollicular scaling on trichoscopy (<i>P</i> &lt; 0.01). However, the two groups had no significant difference during the study. The azathioprine group significantly improved perifollicular erythema on trichoscopy (<i>P</i> = 0.002), but this was not significantly different from the methotrexate group (<i>P</i> = 0.69). Photographic assessment showed that more than 75% of patients in both groups improved without significant differences between the two groups. <i>Conclusion</i>. Methotrexate and azathioprine are two antilymphocyte medications which are both equally effective and well-tolerated for managing LPP. This trial is registered with IRCT20191006045005N2.</p>\\n </div>\",\"PeriodicalId\":11045,\"journal\":{\"name\":\"Dermatologic Therapy\",\"volume\":\"2024 1\",\"pages\":\"\"},\"PeriodicalIF\":3.7000,\"publicationDate\":\"2024-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2024/5556945\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatologic Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1155/2024/5556945\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatologic Therapy","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2024/5556945","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景。扁平苔癣是卡他性脱发的主要病因,其治疗对皮肤科医生来说极具挑战性。这是一种细胞介导的自身免疫性疾病,活化的 T 淋巴细胞会攻击毛囊。研究目的比较甲氨蝶呤和硫唑嘌呤这两种影响淋巴细胞功能的药物在治疗白发性脱发症中的疗效和安全性。方法32 名 LPP 患者被随机分配接受每周 15 毫克的甲氨蝶呤或每公斤 2 毫克的硫唑嘌呤治疗,为期 6 个月。在治疗 2、4 和 6 个月后,使用扁平苔藓活动指数 (LPPAI)、毛囊镜检查和摄影来评估疗效。结果显示甲氨蝶呤组和硫唑嘌呤组的 LPPAI(P <0.001)和毛囊周围鳞屑(P <0.01)均有显著改善。不过,两组在研究期间没有明显差异。硫唑嘌呤组明显改善了毛囊周围红斑(P = 0.002),但与甲氨蝶呤组(P = 0.69)无明显差异。照片评估显示,两组中均有 75% 以上的患者病情有所改善,两组之间无明显差异。结论甲氨蝶呤和硫唑嘌呤这两种抗淋巴细胞药物对治疗 LPP 同样有效,且耐受性良好。本试验注册号为 IRCT20191006045005N2。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Clinical Effectiveness of Two Old Immunosuppressant Drugs, Methotrexate and Azathioprine, in the Treatment of Lichen Planopilaris: A Randomized Clinical Trial

Background. Lichen planopilaris is the leading cause of cicatricial alopecia, and its management is challenging for dermatologists. It is a cell-mediated autoimmune disorder in which activated T-lymphocytes attack hair follicles. Aim. To compare the efficacy and safety of methotrexate versus azathioprine, two medications that affect lymphocyte function, in treating LPP. Methods. 32 LPP patients were randomly assigned to receive either 15 mg/week methotrexate or 2 mg/kg azathioprine for six months. Treatment efficacy was evaluated using the Lichen Planopilaris Activity Index (LPPAI), trichoscopy, and photography after 2, 4, and 6 months of treatment. Results. Both methotrexate and azathioprine groups showed significant improvements in LPPAI (P < 0.001) and perifollicular scaling on trichoscopy (P < 0.01). However, the two groups had no significant difference during the study. The azathioprine group significantly improved perifollicular erythema on trichoscopy (P = 0.002), but this was not significantly different from the methotrexate group (P = 0.69). Photographic assessment showed that more than 75% of patients in both groups improved without significant differences between the two groups. Conclusion. Methotrexate and azathioprine are two antilymphocyte medications which are both equally effective and well-tolerated for managing LPP. This trial is registered with IRCT20191006045005N2.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Dermatologic Therapy
Dermatologic Therapy 医学-皮肤病学
CiteScore
7.00
自引率
8.30%
发文量
711
审稿时长
3 months
期刊介绍: Dermatologic Therapy has been created to fill an important void in the dermatologic literature: the lack of a readily available source of up-to-date information on the treatment of specific cutaneous diseases and the practical application of specific treatment modalities. Each issue of the journal consists of a series of scholarly review articles written by leaders in dermatology in which they describe, in very specific terms, how they treat particular cutaneous diseases and how they use specific therapeutic agents. The information contained in each issue is so practical and detailed that the reader should be able to directly apply various treatment approaches to daily clinical situations. Because of the specific and practical nature of this publication, Dermatologic Therapy not only serves as a readily available resource for the day-to-day treatment of patients, but also as an evolving therapeutic textbook for the treatment of dermatologic diseases.
期刊最新文献
Pharmaceutical Management of Rosacea—An Australian/New Zealand Medical Dermatology Consensus Narrative A3669G Polymorphism of Glucocorticoid Receptor Is More Present in Patients With Pemphigus Vulgaris Than in Healthy Controls and Contributes to Steroid-Resistance Baricitinib for the Treatment of Chronic Pruritus of Unknown Origin Patient Awareness, Education, and Support for Atopic Dermatitis in Egypt and Lebanon: Results of a Physician Survey and Social Analytics Evaluation of Quality of Life in First-Degree Relatives of Patients With Hidradenitis Suppurativa Using Family Dermatology Life Quality Index
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1